4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Multiple Antipsychotic Medication Use in Autism Spectrum Disorder

      brief-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective: The purpose of this study was to explore the use of multiple antipsychotic medications in patients with autism spectrum disorder (ASD) by reviewing the longitudinal medication management of 1100 patients consecutively treated for behavioral symptoms associated with ASD at a tertiary care specialty clinic.

          Methods: We identified all patients with ASD treated with daily doses of two or more antipsychotics for at least two visits at our clinic. For each patient meeting inclusion criteria, diagnostic and demographic data were collected. To evaluate clinical need and effectiveness of antipsychotic medications in this sample, we reviewed symptoms targeted with each antipsychotic medication and concomitant medications prescribed. Clinical Global Impressions-Severity (CGI-S) and Clinical Global Impressions-Improvement (CGI-I) scale ratings had been completed at the time of each visit, and the duration of treatment with antipsychotic medications was determined. To evaluate the safety and tolerability of antipsychotic medication use in ASD, we reviewed reported adverse effects and calculated body mass index (BMI) change with treatment.

          Results: Seventy patients met the inclusion criteria (6.4% of our sample). The majority of patients were moderately to severely ill Caucasian males, as determined by baseline mean CGI-S of 4.7 (SD = 0.8), and were diagnosed with autistic disorder and comorbid intellectual disability. The mean age was 15.1 years (SD = 10.9), the primary targeted symptoms were agitation/irritability, physical aggression, and self-injury. The majority of patients remained on two or more antipsychotics for >1 year. In this population, patients demonstrated greater symptomatic improvement and generally tolerated treatment without significant adverse effects.

          Conclusions: The use of two or more antipsychotic medications may be increasingly common in patients with ASD. This retrospective study demonstrates that this treatment approach may be of some clinical benefit, and is generally well tolerated. Prospective studies focusing on the efficacy and safety of concomitant antipsychotic medication usage in ASD should be considered.

          Related collections

          Author and article information

          Journal
          J Child Adolesc Psychopharmacol
          J Child Adolesc Psychopharmacol
          cap
          Journal of Child and Adolescent Psychopharmacology
          Mary Ann Liebert, Inc. (140 Huguenot Street, 3rd FloorNew Rochelle, NY 10801USA )
          1044-5463
          1557-8992
          01 February 2017
          01 February 2017
          : 27
          : 1
          : 91-94
          Affiliations
          [ 1 ]Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine , Cincinnati, Ohio.
          [ 2 ] Lurie Center for Autism , Departments of Psychiatry and Pediatrics, Massachusetts General Hospital and MassGeneral Hospital for Children, Harvard Medical School , Boston, Massachusetts.
          Author notes

          Statistical Consultant: Paul A. Horn.

          Funding: This work was supported by the Indiana University School of Medicine Department of Psychiatry. Dr. Wink's current research is supported by Autism Speaks, the John Merck Fund, Riovant Sciences Ltd., the Simons Research Foundation, SynapDx, and the United Stated Department of Defense.

          Address correspondence to: Logan K. Wink, MD, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine 3333 Burnet Avenue MLC 4002, Cincinnati, OH 45229, E-mail: logan.wink@ 123456cchmc.org
          Article
          PMC5335810 PMC5335810 5335810 10.1089/cap.2015.0123
          10.1089/cap.2015.0123
          5335810
          26465194
          2bb98f2e-0d9c-4e31-86c3-f5efcf03285c
          Copyright 2017, Mary Ann Liebert, Inc.
          History
          Page count
          Tables: 2, References: 14, Pages: 4
          Categories
          Brief Reports

          irritability,autism,autism spectrum disorder,antipsychotics,psychopharmacology

          Comments

          Comment on this article